Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM6IYAT)

Drug Name
PMID28270010-Compound-Figure21-b Drug Info
Indication
Disease Entry ICD 11 Status REF
Brain metastases 2D50 Patented [1]
Cross-matching ID
PubChem CID
71731823
ChEBI ID
CHEBI:143117
CAS Number
CAS 1454846-35-5
TTD Drug ID
DM6IYAT
ACDINA Drug ID
D01222

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
ALK tyrosine kinase receptor (ALK) TTPMQSO ALK_HUMAN Inhibitor [1]
Proto-oncogene c-Ros (ROS1) TTSZ6Y3 ROS1_HUMAN Inhibitor [1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Proto-oncogene c-Ros (ROS1) DTT ROS1 5.511 4.406 4.973 4.823
ALK tyrosine kinase receptor (ALK) DTT ALK 5.329 3.897 4.178 4.943
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Brain metastases
ICD Disease Classification 2D50
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Proto-oncogene c-Ros (ROS1) DTT ROS1 1.45E-44 -1.01 -1.9
ALK tyrosine kinase receptor (ALK) DTT ALK 7.19E-15 0.18 0.61
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.